BioCure Inc.
www.biocure.com
Latest From BioCure Inc.
Biocompatibles: Crossing Over to the Convergence Side in Cancer and Stroke
Biocompatibles has re-invented itself a third time, exiting traditional device markets for riskier drug-device convergence plays in oncology and stroke, clinical areas dominated by drug therapy. This move has caught drug companies' attention clinically, but will Big Pharma validate Biocompatibles' strategy commercially?
Biocompatibles: The Perils of Re-Inventing a Public Company
The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears and apply their original or another technooloogy to a different clinical need. Indeed, Biocompatibles is now workiing on its third primary therapeutic areas--cancer--having previously sold off its first two businesses, in ophthalmology and then, convinced it was too far behind in drug-eluting stents, cardiovascular. This new growth area is being driven by the company's general expertise in polymer technology and drug delivery.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Implantable Devices
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- BioCure Inc.
- Senior Management
-
Adrian Hunter, CEO
Thomas Hirt, PhD, VP, R&D - Contact Info
-
BioCure Inc.
Phone: (678) 966-3400
2975 Gateway Dr., Ste. 100
Norcross, GA 30071
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioCure Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice